Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U4 small nuclear 31, pseudogene (RNU4-31P) is a non-protein-coding pseudogene, annotated as a member of the U4 small nuclear RNA pseudogenes, and does not code for a functional protein or RNA product involved in canonical spliceosomal or other biological roles[1][5]. There is no evidence this gene has any established biological function, disease role, or utility as a therapeutic target. No small molecules or drugs are known to interact with this locus, nor is it implicated as a biomarker or safety concern. The gene is listed in genome resources primarily as a locus annotation, and not as a functional or validated biological entity[1][5]. Analysis and Justification: - This entity is a pseudogene, not a canonical protein, enzyme, receptor, transporter, or even functional non-coding RNA[1][5]. - No known involvement in biological functions or disease, no validated protein/RNA product, and no druggability is described. - It is not considered a therapeutic target, and there is no common evidence of biomolecular or pharmaceutical relevance. - The name and abbreviation are correct and used in major databases[1][5]. - This entry could create confusion with functional U4 small nuclear RNAs (such as RNU4-2), which are genuine, essential spliceosomal RNAs and causal in disease when mutated[3][4][6][7]. However, RNU4-31P refers only to a pseudogene locus and is not itself implicated. - Therefore, is_incorrect is true as this target is not a functional drug target or relevant biomolecule, but merely a pseudogene genomic annotation. Summary: RNU4-31P represents a non-functional pseudogene with no clinical, mechanistic, or therapeutic significance. It should not be considered a drug or biomarker target, and is not implicated in any characterized biological or disease processes[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 31, pseudogene (RNU4-31P).